First Patient Dosed in LIXTE’s LB-100 Clinical Trial
PASADENA, Calif. — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has announced that the first patient has been dosed in an exciting new clinical trial designed to treat unresponsive (MSI Low) metastatic colorectal cancer. This study is being carried out in partnership with the Netherlands Cancer Institute (NKI) and is supported by F. Hoffmann-La Roche Ltd. (“Roche”).
Clinical Trial Overview
This clinical trial, designated as NCT06012734, will evaluate LIXTE's leading compound, LB-100, in conjunction with Roche's atezolizumab (Tecentriq), a PDL1 inhibitor. The study is part of the imCORE Network, a global initiative aimed at accelerating cancer immunotherapy research through collaboration between academia and industry.
Trial Objectives
The main objective of this clinical trial is to assess how effective immunotherapy is for about 85 percent of colorectal cancer patients who have not responded to standard treatment methods. Dr. Neeltje Steeghs, a medical oncologist at NKI, emphasized the trial's goal of providing effective treatment options for this particular patient group.
CEO's Remarks on the Trial Launch
Bas van der Baan, CEO of LIXTE, expressed his enthusiasm about the launch of this important trial, which is funded by Roche. He noted that this represents the second clinical trial where LB-100 is being combined with immunotherapy, following a recent collaboration with GSK focused on clear cell ovarian cancer.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to developing new therapies for cancer. Its innovative lead compound, LB-100, is recognized for its ability to inhibit PP2A and has shown a favorable safety profile along with potential anti-cancer effects in patients. Researchers have thoroughly assessed its capabilities, and early results are promising for improving existing chemotherapy and immunotherapy treatments.
Revolutionary Cancer Treatment Approach
The company is at the forefront of a groundbreaking approach to cancer treatment that revolves around the concept of activation lethality. This strategy aims to transform therapeutic methods for various cancers, including colorectal, ovarian, and sarcoma cancers. LIXTE's approach is backed by a strong patent portfolio, safeguarding its innovative processes.
Contact Information and Further Details
For more information about LIXTE, potential investors, or interested parties can reach out through the following contact methods:
Contact Information:
Email: info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Additionally, inquiries can be directed to PondelWilkinson Inc. Investor Relations at pwinvestor@pondel.com.
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
Frequently Asked Questions
What is the purpose of the clinical trial involving LB-100?
The trial aims to evaluate the effectiveness of LB-100 combined with atezolizumab for treating unresponsive metastatic colorectal cancer.
Which organizations are collaborating on this clinical trial?
The clinical trial is a collaboration between LIXTE Biotechnology Holdings, Inc. and the Netherlands Cancer Institute, with support from Roche.
What is LB-100?
LB-100 is LIXTE's lead compound that inhibits PP2A, which has shown potential in enhancing anticancer therapies.
How does this trial fit into LIXTE's broader strategy?
This trial represents a strategic initiative for LIXTE to integrate its innovative treatment approaches within the developing landscape of cancer immunotherapy.
What other clinical trials is LIXTE currently conducting?
LIXTE is also conducting clinical trials targeting other cancers, including ovarian and sarcoma cancers.
